0AB6 Stock Overview
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.70 |
| 52 Week High | €13.31 |
| 52 Week Low | €11.09 |
| Beta | 0.58 |
| 1 Month Change | 3.09% |
| 3 Month Change | -11.37% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0AB6 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.5% | 5.0% | 1.4% |
| 1Y | n/a | 5.0% | 1.1% |
Return vs Industry: Insufficient data to determine how 0AB6 performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0AB6 performed against the UK Market.
Price Volatility
| 0AB6 volatility | |
|---|---|
| 0AB6 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0AB6 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0AB6's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 42 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer.
Hyloris Pharmaceuticals SA Fundamentals Summary
| 0AB6 fundamental statistics | |
|---|---|
| Market cap | €327.60m |
| Earnings (TTM) | -€15.76m |
| Revenue (TTM) | €2.81m |
116.4x
P/S Ratio-20.8x
P/E RatioIs 0AB6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0AB6 income statement (TTM) | |
|---|---|
| Revenue | €2.81m |
| Cost of Revenue | €93.00k |
| Gross Profit | €2.72m |
| Other Expenses | €18.48m |
| Earnings | -€15.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 96.70% |
| Net Profit Margin | -560.13% |
| Debt/Equity Ratio | 0% |
How did 0AB6 perform over the long term?
See historical performance and comparison